Core Insights - Silo Pharma has selected the Alphaledger/Simplify Target 12% Distribution Fund as a key part of its real-world asset investment strategy, aiming to diversify its treasury and integrate digital assets [1][3] - The Alphaledger T12 Fund is designed to provide high monthly income through a diversified portfolio of alternative income-generating strategies, operating on the Solana blockchain for efficiency and low costs [2][3] - The investment reflects a broader trend among institutions to incorporate tokenized real-world assets into their balance sheets, enhancing transparency and compliance in financial products [3] Company Overview - Silo Pharma is a developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved medical conditions, including stress-induced psychiatric disorders and chronic pain [7] - The company is engaged in innovative therapeutic programs, including SPC-15 for PTSD and SP-26 for fibromyalgia, and collaborates with leading universities for research [7] Fund Overview - The Alphaledger T12 Fund is a digital-native investment vehicle that provides access to tokenized real-world assets, leveraging blockchain technology for efficient investment pathways [2][4] - Managed by Alphaledger Investment Management LLC, the fund aims to transform investing through blockchain-powered asset tokenization [5][6]

Product Features - Helius 发布了新的交易发送器，旨在提高交易速度和可靠性 [1] - 该交易发送器针对七个主要地区的网络进行了优化 [1] - 支持并行发送到 Jito 和 SWQOS，或仅选择 SWQOS [1] - 用户可以访问 Solana 上 staking 比例最高的验证器 [1] - 该服务目前免费，无需任何积分 [1]

Group 1 - BTCS Inc. has been included in the Russell Microcap Index, enhancing its visibility and credibility in the market [1][2][3] - The inclusion is seen as a significant milestone in BTCS's growth trajectory, expected to broaden its reach and attract new audiences [3] - BTCS focuses on Ethereum infrastructure and operates a vertically-integrated blockchain strategy, which includes staking and block building [3][6] Group 2 - The Russell Microcap Index serves as a benchmark for the microcap segment of the U.S. equity market, providing validation for companies included [2][5] - BTCS's strategy is supported by its DeFi/TradFi flywheel framework, aimed at driving scalable revenue growth and enhancing ETH per share [3] - The company operates Builder+, an advanced block-building operation, and ChainQ, an AI-powered blockchain data analytics platform [6][7]